"We are proud to lead worldwide efforts in this next phase of CAR-T treatment for lymphoma patients and bring this critical innovation to as many patients as possible,” said Frederick Locke, M.D., vice chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy.
"I think it’s a potential game-changer because we’ve actually shown that people lose this specific immune response early in the process of breast cancer development," says Brian Czerniecki, M.D., the chair of the department of Breast Oncology.
Contact the Public Relations Team:
Kim Polacek, APR, CPRC
Research, Clinical Trials, Government, M2Gen/ORIEN
Clinical, Diversity, Sports & Hospital Partnerships
Clinical, Sports & Community Partnerships, Supportive Care
Nancy Gay, APR
Clinical, International Referrals, Nursing, Finance